Table 1.
Various DAPT regimens and reported ischemic and hemorrhagic complications of selected flow diversion publications.
| PITA68 | PUFS69 | PREMIER70 | SAFE71 | SCENT72 | PARAT73 | Adeeb et al.29 | Atallah et al.74 | Griessenauer et al.75 | Moore et al.76 | Soize et al.77 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study type | P / MC | P / MC | P / MC | P / MC | P / MC | P / RCT | R | R | R | R | R |
| Aneurysms | 31 | 109 | 141 | 103 | 180 | 144 | 402 | 396 | 114 | 103 | 80 |
| PreTx AntiplateletDosage | Not reported | ASA 325 mg/d x2 ds AND CLO 75 mg/d x7 dsOR CLO 600 mg x1d | ASA min 81 mg/d x7 dsANDCLO min 75 mg/d x7 ds | Not reported | ASA min 75 mg/d AND CLO 75 mg/d x5 ds | ASA 300 mg/d AND CLO 75 mg/d x3 ds | ASA 325 mg/d AND CLO 75 mg/d daily3 to 14 dsALT: CLO 600mgx1 or ticagrelor 90 mg/BID for nonresponders | ASA min 75 mg/d AND CLO 75 mg/d x10 ds ALT: ASA 325-650mg x1 AND CLO 600 mg x1 OR PRA 40–60 mg x1 OR TIC 90 mg x1 | ASA min 81 mg/d AND CLO 75 mg/d min x10 ds | ASA 325 mg/d AND CLO 75 mg/d daily x14 ds OR Nonresponders TIC 180 mg x1 ∼3 h prior | ASA 325 mg/d AND CLO 75 mg/d x5 ds OR ASA 325 mg/d AND TIC 90 mg/BID x2ds |
| PostTx AntiplateletDosage | ASA 100 mg/d x180 dsCLO 75 mg/d x30 ds | ASA 325 mg d x 6 msCLO 75 mg/d X3 ms | ASA min 81 mg/dx6 msCLO 75 mg/d x3 ms | Not reported | ASA min 75 mg/d indefinitelyAND CLO 75 mg/d or equivalent x6 ms | <6 wks: ASA 300 mg/d AND CLO 75 mg/d; 6 wks to 3 ms: ASA 100 mg/d AND CLO 75 mg/d; then only ASA | DAPT x3 msthen only ASA | CLO 75 mg/d OR PRA 10 mg/d OR TIC 90 mg/BIDx6 to 12 ms | DAPT x3-6 ms | DAPT x3 msthen only ASA | DAPT x3 ms |
| PhenotypingTargets | None | None | VerifyNow PRU 60 to 200 | None | Platelet aggregometry30% to 90% | None | Nonresponders if PRU >208 | Nonresponders if PRU <30% inhibition | None | Aggregometry >50% with 5 μM ADP OR VerifyNow PRU >208 | None |
| GenotypingAlternative | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done | Not done |
| Follow-up | 6 mo | 6 ms and 5 yr | 1 yr | 14.7 ms | 12 ms | 6 ms | Not specified | 15.8 ms | 6.5 ms | 7.2 ms | 1 m |
| Thromboembolism | 6.7% | 2.8% | 0.7% | 6.8% | 6.1% | Tubridge 10% SAC 10% | ASA CLO 5.6%ASA CLO plus BOOST 9.8%ASA TIC 2.7% | ASA CLO 7.5%ASA PRA OR TIC 4.5% | All: 8.5% | ASA CLO 6%ASA TIC 4.2% | ASA CLO 5%ASA TIC 12.5% |
| Hemorrhage | 0% | 1.9% | 1.4% | 1% | 2.8% | Tubridge 6%SAC 3% | ASA CLO 3.2%ASA CLO plus BOOST 2%ASA TIC 0% | ASA CLO 5.6%ASA PRA OR TIC 0% | All: 1 patient | ASA CLO 1.9%ASA TIC 0% | ASA CLO 5%ASA TIC 5% |